Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 32.

Niedrig, D F; Bucklar, G; Fetzer, M; Mächler, S; Gött, C; Russmann, S (2016). Paracetamol overdosing in a tertiary care hospital: implementation and outcome analysis of a preventive alert programme. Journal of Clinical Pharmacy and Therapeutics, 41(5):515-518.

Russmann, S; Kullak-Ublick, G A; Weiler, S; Stoller, R; Egbring, M (2016). Arzneimittelsicherheit. In: Siepmann, T; Kirch, W; Kullak-Ublick, G A. Arzneimitteltherapie : Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: George Thieme Verlag, 71-99.

Aellig, N; Krüger, B; Schwartz, T; Kullak-Ublick, G A; Schmid-Grendelmeier, P; Russmann, S (2014). Chlorhexidin-Allergie. Swiss Medical Forum, 14(15):321-322.

Weiss, T; Müller, D; Marti, I; Happold, C; Russmann, S (2013). Gamma-hydroxybutyrate (GHB) and topiramate-clinically relevant drug interaction suggested by a case of coma and increased plasma GHB concentration. European Journal of Clinical Pharmacology, 69(5):1193-1194.

Russmann, S; Kullak-Ublick, G A (2012). Beurteilung und Meldung medikamentöser Leberschäden. Vigilance-News, (10):9-14.

Russmann, S; Kullak-Ublick, G A (2012). Arzneimittelsicherheit. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 27-31.

Russmann, S (2012). Arzneimittelsicherheit in klinischen Studien. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 35-38.

Egbring, M; Russmann, S; Kullak-Ublick, G A (2012). Clinical decision support systems. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 49-52.

Zorina, O I; Haueis, P; Semmler, A; Marti, I; Gonzenbach, R R; Guzek, M; Kullak-Ublick, G A; Weller, M; Russmann, S (2012). Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients. Pharmacoepidemiology and Drug Safety, 21(8):872-880.

Haueis, P; Russmann, S; Zorina, O I; Grohmann, R; Kullak-Ublick, G A; Jaquenoud Sirot, E; Russmann, H (2012). Coprescription of levodopa with antipsychotics in a population of 84 596 psychiatric inpatients from 1994 to 2008. Pharmacopsychiatry, 45(04):127-132.

Taegtmeyer, A B; Curkovic, I; Corti, N; Rosen, C; Egbring, M; Russmann, S; Gantenbein, A R; Weller, M; Kullak-Ublick, G A (2012). Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients. Swiss Medical Weekly, 142:w13615.

Greil, W; Häberle, A; Haueis, P; Grohmann, R; Russmann, S (2012). Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. Journal of Affective Disorders, 136(3):534-542.

Russmann, S (2012). Pharmakoepidemiologie. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 42-48.

Sift Carter, R; Russmann, S; Stoller, R (2012). Pharmakovigilanz. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 38-41.

Russmann, S (2012). Risiko von Arzneimittelinteraktionen - Therapie optimieren, Interaktionen vermeiden. Medical Tribune, (10):25-26.

Sift Carter, R; Stoller, R; Russmann, S (2012). Unerwünschte Arzneimittelwirkungen. In: Kullak-Ublick, G A; Siepmann, T; Kirch, W. Arzneimitteltherapie: Wirksamkeit - Sicherheit - Praktische Anwendung. Stuttgart: Thieme, 32-35.

Vavricka, B M P; Baumberger, P; Russmann, S; Kullak-Ublick, G A (2011). Diagnosis of melanoma under concomitant natalizumab therapy. Multiple Sclerosis, 17(2):255-256.

Guzek, M; Zorina, O I; Semmler, A; Gonzenbach, R R; Huber, M; Kullak-Ublick, G A; Weller, M; Russmann, S (2011). Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System). Pharmacoepidemiology and Drug Safety, 20(9):930-938.

Haueis, P; Greil, W; Huber, M; Grohmann, R; Kullak-Ublick, G A; Russmann, S (2011). Evaluation of drug interactions in a large sample of psychiatric inpatients: A data interface for mass analysis with clinical decision support software. Clinical Pharmacology and Therapeutics, 90(4):588-596.

Frölich, T; Zorina, O; Fontana, A O; Kullak-Ublick, G A; Vollenweider, A; Russmann, S (2011). Evaluation of medication safety in the discharge medication of 509 surgical inpatients using electronic prescription support software and an extended operational interaction classification. European Journal of Clinical Pharmacology, 67(12):1273-1282.

Gonzenbach, R R; Taegtmeyer, A B; Luft, A; Russmann, S (2011). Fluoxetine and motor recovery after ischaemic stroke. Lancet Neurology, 10(6):499-500.

Grattagliano, I; Russmann, S; Diogo, C V; Bonfrate, L; Oliveira, P J; Wang, D Q H; Portincasa, P (2011). Mitochondria in chronic liver disease. Current Drug Targets, 12(6):879-893.

Russmann, S; Curkovic, I; Huber, M (2010). Risiken und Nebenwirkungen durch Non Compliance. Therapeutische Umschau, 67(6):303-307.

Egbring, M; Kullak-Ublick, G A; Russmann, S (2010). Phynx: an open source software solution supporting data management and web-based patient-level data review for drug safety studies in the general practice research database and other health care databases. Pharmacoepidemiology and Drug Safety, 19(1):38-44.

Bihl, F; Russmann, S; Gurtner, V; Di Giammarino, L; Pizzi-Bosman, L; Michel, M; Cerny, A; Hadengue, A; Majno, P; Giostra, E; Castelli, D; Mentha, G (2010). Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. BMC Gastroenterology, 10:71.

Russmann, S; Jetter, A; Kullak-Ublick, G A (2010). Pharmacogenetics of drug-induced liver injury. Hepatology, 52(2):748-761.

Motsko, S P; Russmann, S; Ming, E E; Singh, V P; Vendiola, R; Jones, J K (2009). Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. Pharmacoepidemiology and Drug Safety, 18(12):1214-1222.

Russmann, S; Kullak-Ublick, G A; Grattagliano, I (2009). Current concepts of mechanisms in drug-induced hepatotoxicity. Current Medicinal Chemistry, 16(23):3041-3053.

Russmann, S; Szeless, T; Bock, A; Kullak-Ublick, G A (2009). Natriumphosphat enthaltende Darmreinigungsmittel – eine Gefahr für die Niere? Swiss Medical Forum, 9(18):336-339.

Russmann, S; Lamerato, L; Motsko, S P; Pezzullo, J C; Faber, M D; Jones, J K (2008). Risk of further decline in renal function after the use of oral sodium phosphate or polyethylene glycol in patients with a preexisting glomerular filtration rate below 60 ml/min. American Journal of Gastroenterology, 103(11):2707-2716.

Serra, A L; Braun, S C; Starke, A; Savoca, R; Hersberger, M; Russmann, S; Corti, N; Wüthrich, R P (2008). Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. American Journal of Transplantation, 8(4):803-810.

Russmann, S. Methodological options for the evaluation of drug safety: from spontaneous reports to pharmacoepidemiology. 2008, University of Zurich, Faculty of Medicine.

This list was generated on Thu Sep 21 11:37:18 2017 CEST.